Skip to main content
NVDA-2.44%AAPL+3.15%GOOGL+0.44%MSFT-0.14%AMZN-0.22%TSM-1.32%SPCX+0.84%AVGO-0.58%META-1.20%TSLA-0.40%SKHY-4.06%MU-4.40%BRK-B-0.25%LLY-0.13%JPM-0.68%WMT-0.14%AMD-3.07%V-0.22%XOM+0.64%ASMLa-1.66%JNJ-0.16%INTC-4.61%MA-0.60%0700.HK-1.94%1398.HK+0.79%ORCL-3.99%ABBV+0.96%BAC-0.52%CSCO-1.09%CVX-0.39%COST-0.17%KO+0.61%LRCX-4.98%CAT-1.42%AP2d-1.55%0005.HK-0.78%AMAT-2.60%UNH-1.05%HSBA.L-1.30%DELL-3.48%PG+0.46%MS-1.08%GE-0.65%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.26%HD-1.88%0939.HK+1.66%GS-1.16%NZDJPY-2.62%AUDJPY-1.83%CHFJPY-1.60%NZDCAD-1.47%EURNZD+1.44%NZDUSD-1.42%GBPNZD+1.39%GBPJPY-1.25%USDJPY-1.23%EURJPY-1.23%CADJPY-1.17%NZDCHF-1.05%USDZAR+0.97%USDNOK+0.91%USDSEK+0.88%AUDNZD+0.82%EURZAR+0.80%EURNOK+0.73%GBPZAR+0.72%EURSEK+0.71%AUDCAD-0.69%AUDDKK-0.64%EURAUD+0.61%AUDUSD-0.61%USDTHB+0.60%CHFNOK+0.57%GBPAUD+0.57%CHFSEK+0.55%AUDSGD-0.54%USDMXN+0.51%USDPLN+0.43%NZDSGD-0.42%CADCHF+0.42%GBPTRY+0.41%NOKJPY-0.40%USDCHF+0.38%EURCHF+0.37%GBPCHF+0.34%GBPHKD+0.32%GBPMXN-0.28%USDSGD+0.27%EURPLN+0.26%SGDJPY+0.24%AUDCHF-0.23%NZDMXN-0.21%EURHKD-0.18%USDDKK+0.17%USDILS+0.16%USDTRY+0.11%EURSGD+0.10%USDCNH+0.10%GBPCAD-0.09%AUDNOK+0.09%PLNJPY+0.08%CHFSGD-0.06%EURCAD-0.06%EURCNH-0.05%EURCZK-0.05%USDCAD-0.05%USDCOP-0.04%EURGBP+0.04%GBPUSD-0.02%USDHKD+0.02%GBPSGD+0.02%EURUSD0.00%EURDKK0.00%XPTUSD-5.92%XAGUSD-5.06%GAGUSD-5.06%UKOIL+4.96%HG1-4.82%USOIL+4.74%XNGUSD+1.63%GAUUSD-1.55%XAUUSD-1.55%SUGAR0.00%S10.00%COFFEE0.00%BTCUSD-1.37%ETHUSD-0.03%USDTUSD-0.02%XRPUSD-2.84%SOLUSD-1.64%TRXUSDT+0.24%ZECUSDT-8.36%DOGEUSD-2.56%XMRUSDT+0.47%LINKUSD-1.12%XLMUSD-1.17%BCHUSDT-9.67%LTCUSD-1.50%UNIUSD-1.03%TONUSD+24.88%HBARUSDT-2.32%SUIUSD-3.99%TAOUSDT-5.17%AAVEUSD-2.21%DOTUSDT-1.56%ICPUSDT-0.72%ONDOUSDT-2.95%WLDUSDT-2.43%ATOMUSDT-2.11%ARBUSDT+0.11%JUPUSDT-3.39%INJUSDT-1.83%STXUSDT-4.16%FETUSDT-2.62%TIAUSDT-0.34%PYTHUSDT-0.97%SEIUSDT-6.02%IMXUSDT-3.06%GRTUSDT-3.05%WIFUSDT-4.89%OPUSDT-3.00%POLUSDT-4.41%IOTAUSDT-3.42%AXSUSDT-2.25%FARTCOINUSDT-2.86%EOSUSDT-2.41%DYDXUSDT-1.72%ORDIUSDT-0.35%GALAUSDT-3.09%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.44%AAPL+3.15%GOOGL+0.44%MSFT-0.14%AMZN-0.22%TSM-1.32%SPCX+0.84%AVGO-0.58%META-1.20%TSLA-0.40%SKHY-4.06%MU-4.40%BRK-B-0.25%LLY-0.13%JPM-0.68%WMT-0.14%AMD-3.07%V-0.22%XOM+0.64%ASMLa-1.66%JNJ-0.16%INTC-4.61%MA-0.60%0700.HK-1.94%1398.HK+0.79%ORCL-3.99%ABBV+0.96%BAC-0.52%CSCO-1.09%CVX-0.39%COST-0.17%KO+0.61%LRCX-4.98%CAT-1.42%AP2d-1.55%0005.HK-0.78%AMAT-2.60%UNH-1.05%HSBA.L-1.30%DELL-3.48%PG+0.46%MS-1.08%GE-0.65%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.26%HD-1.88%0939.HK+1.66%GS-1.16%NZDJPY-2.62%AUDJPY-1.83%CHFJPY-1.60%NZDCAD-1.47%EURNZD+1.44%NZDUSD-1.42%GBPNZD+1.39%GBPJPY-1.25%USDJPY-1.23%EURJPY-1.23%CADJPY-1.17%NZDCHF-1.05%USDZAR+0.97%USDNOK+0.91%USDSEK+0.88%AUDNZD+0.82%EURZAR+0.80%EURNOK+0.73%GBPZAR+0.72%EURSEK+0.71%AUDCAD-0.69%AUDDKK-0.64%EURAUD+0.61%AUDUSD-0.61%USDTHB+0.60%CHFNOK+0.57%GBPAUD+0.57%CHFSEK+0.55%AUDSGD-0.54%USDMXN+0.51%USDPLN+0.43%NZDSGD-0.42%CADCHF+0.42%GBPTRY+0.41%NOKJPY-0.40%USDCHF+0.38%EURCHF+0.37%GBPCHF+0.34%GBPHKD+0.32%GBPMXN-0.28%USDSGD+0.27%EURPLN+0.26%SGDJPY+0.24%AUDCHF-0.23%NZDMXN-0.21%EURHKD-0.18%USDDKK+0.17%USDILS+0.16%USDTRY+0.11%EURSGD+0.10%USDCNH+0.10%GBPCAD-0.09%AUDNOK+0.09%PLNJPY+0.08%CHFSGD-0.06%EURCAD-0.06%EURCNH-0.05%EURCZK-0.05%USDCAD-0.05%USDCOP-0.04%EURGBP+0.04%GBPUSD-0.02%USDHKD+0.02%GBPSGD+0.02%EURUSD0.00%EURDKK0.00%XPTUSD-5.92%XAGUSD-5.06%GAGUSD-5.06%UKOIL+4.96%HG1-4.82%USOIL+4.74%XNGUSD+1.63%GAUUSD-1.55%XAUUSD-1.55%SUGAR0.00%S10.00%COFFEE0.00%BTCUSD-1.37%ETHUSD-0.03%USDTUSD-0.02%XRPUSD-2.84%SOLUSD-1.64%TRXUSDT+0.24%ZECUSDT-8.36%DOGEUSD-2.56%XMRUSDT+0.47%LINKUSD-1.12%XLMUSD-1.17%BCHUSDT-9.67%LTCUSD-1.50%UNIUSD-1.03%TONUSD+24.88%HBARUSDT-2.32%SUIUSD-3.99%TAOUSDT-5.17%AAVEUSD-2.21%DOTUSDT-1.56%ICPUSDT-0.72%ONDOUSDT-2.95%WLDUSDT-2.43%ATOMUSDT-2.11%ARBUSDT+0.11%JUPUSDT-3.39%INJUSDT-1.83%STXUSDT-4.16%FETUSDT-2.62%TIAUSDT-0.34%PYTHUSDT-0.97%SEIUSDT-6.02%IMXUSDT-3.06%GRTUSDT-3.05%WIFUSDT-4.89%OPUSDT-3.00%POLUSDT-4.41%IOTAUSDT-3.42%AXSUSDT-2.25%FARTCOINUSDT-2.86%EOSUSDT-2.41%DYDXUSDT-1.72%ORDIUSDT-0.35%GALAUSDT-3.09%NOTUSDT-2.97%RONINUSDT-2.64%
VP

Vertex Pharmaceuticals Incorporated (VX1d)

FRA • Healthcare

€445.5
-€4.1 (-0.9%)
Market closed

September 10, 2026 at 15:30 UTC

Open€452.15
Day Range€445.3 - €453.15
Avg. Volume (3M)70
Market Cap€113B
P/E Ratio25.7
52 Week Range
€320.75€480.4

Interactive Chart

19:08:17 UTC

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned€3.3B100%
Gross Profitminus cost of goods€2.8B85%
Operating Incomeminus R&D and overhead€1.2B38%
Net Incomeminus taxes and the rest€1.1B33%

In plain terms: out of every €100 in revenue, Vertex Pharmaceuticals Incorporated keeps €33 as net profit.

Fundamentals & Financials

Revenue (TTM)
€12.6B
Net Income (TTM)
€4.4B
EPS (TTM)
€17.31
ROA (TTM)
16.06%
Current Ratio
3.19
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

€1.96Q4 2019
€2.1Q1 2020
€2.82Q2 2020

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q2 2020

Vertex Pharmaceuticals’ revenue rose 12.6% to about $3.3 billion in the second fiscal quarter of 2026, reported Aug. 3 and based on preliminary results, while adjusted EPS of $4.14 came in line with the $4.15 estimate, -0.2%, and was up 7.8% from $3.84 a year ago. Net income increased 6.6% to about $1.1 billion from about $1.0 billion a year ago, operating income came to about $1.3 billion, gross margin was near 86%, and operating margin was around 38%. Operating cash flow came to about $1.1 billion, the company repurchased about $474 million of stock, and consensus for the next period calls for EPS of $4.16.

View full earnings history

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated trades on XETRA as VX1.DE and operates in biotechnology, developing and commercializing medicines centered on cystic fibrosis. In FY2025, the company generated $12.1 billion in revenue. Its marketed portfolio is led by CFTR modulators that treat defined cystic fibrosis mutation groups, and the company was founded in 1989 in Boston, Massachusetts.

Name
Vertex Pharmaceuticals Incorporated
CEO
Reshma Kewalramani
Website
www.vrtx.com
Industry
Healthcare
Year Founded
1989
Employees
6,400

Today's Snapshot

AI-generated

The day ended with VX1d slightly lower at 448.00, in line with a flat sector. Shares changed hands at under a tenth of its usual level. Vertex presented its kidney-drug pipeline at a Wells Fargo bank healthcare conference.

Trading Volume

Below 10d avg (35)

3

vs S&P 500 Today

Moderate Outperformance

+0.11%

Updated: September 10, 2026 at 14:03 UTC

VX1d Headlines

Vertex to buy Crinetics for $10 billion

July 6, 2026

3 min read

Biotech ETFs Flash Classic Reversal Signal

April 1, 2026

2 min read

Executives File New SEC Form 144 Sales

February 27, 2026

4 min read
View All News

Technical Indicators

4 Buy2 Neutral2 Sell
VX1d registers a buy bias supported by its position above medium- and long-term averages even as short-term moving averages lag. Momentum readings are mixed — RSI is neutral and the MACD is flat — while the ADX near 19 indicates no strong directional trend yet. The market price sits under near-term averages but is roughly at the 50-day level, suggesting medium-term support, and volatility is contained by a modest ATR. On‑balance volume is weak, so breadth is not confirming strength. Technical takeaway: Buy bias relies on longer-term moving average support amid subdued momentum.
All signals
  • EMA (5 indicators)$406.83 - $461.24
    Buy
  • RSI (14)42.72
    Neutral
  • Stochastic %K (14, 3, 3)0.74
    Buy
  • MACD Level (12, 26)4.65
    Neutral

Peers & Related Assets

GIS.DEGilead Sciences, Inc.
PFE.FPfizer Inc.
PFE.DEPfizer Inc.
BRM.DEBristol-Myers Squibb Company
CVS.DECVS Health Corporation
2M6.DEMedtronic Plc
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.